Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients

Cancer

Volumn 122, Issue 9, 2016, Pages 1370-1379

  Song, Young Shin ^a   Lim, Jung Ah ^a,b   Choi, Hoonsung ^a,c   Won, Jae Kyung ^a   Moon, Jae Hoon ^a,d   Cho, Sun Wook ^a   Lee, Kyu Eun ^a   Park, Young Joo ^a   Yi, Ka Hee ^a,e   Park, Do Joon ^a   Seo, Jeong Sun ^a  

^a Seoul National University   (South Korea)

^b National Medical Center   (South Korea)

^c Kangwon National University   (South Korea)

^d Seoul National University Bundang Hospital   (South Korea)

^e Seoul National University Boramae Hospital   (South Korea)

Author keywords

differentiated thyroid cancer; mortality; prognosis; recurrence; telomerase reverse transcriptase (TERT) promoter mutations

Indexed keywords

B RAF KINASE; RAS PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TELOMERASE;

ADULT; AGE; AMERICAN THYROID ASSOCIATION; ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; DISEASE SPECIFIC MORTALITY RATE; DISTANT METASTASIS; FEMALE; FOLLOW UP; GENE MUTATION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; RECURRENT DISEASE; RISK ASSESSMENT; SCORING SYSTEM; TERT GENE; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; ONCOGENE RAS; PATHOLOGY; PROGNOSIS; THYROID TUMOR; TIME FACTOR; TUMOR RECURRENCE;

ADULT; FEMALE; FOLLOW-UP STUDIES; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; TELOMERASE; THYROID NEOPLASMS; TIME FACTORS;

EID: 84960388175     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29934     Document Type: Article

References (26)

1. Howlader N, Noone AM, Krapcho M, et al., SEER Cancer Statistics Review, 1975-2012. Bethesda, MD: National Cancer Institute; 2015.
2. Ahn HS, Kim HJ, Welch HG,. Korea's thyroid-cancer "epidemic"-screening and overdiagnosis. N Engl J Med. 2014; 371: 1765-1767.
3. Schlumberger MJ,. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998; 338: 297-306.
4. Cho SW, Choi HS, Yeom GJ, et al., Long-term prognosis of differentiated thyroid cancer with lung metastasis in Korea and its prognostic factors. Thyroid. 2014; 24: 277-286.
5. Liu X, Bishop J, Shan Y, et al., Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 2013; 20: 603-610.
6. Xing M, Liu R, Liu X, et al., BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol. 2014; 32: 2718-2726.
7. Xing M, Liu R, Bishop J,. TERT promoter and BRAF mutations cooperatively promote papillary thyroid cancer-related mortality. Thyroid. 2014; 24: A131.
8. Liu T, Wang N, Cao J, et al., The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene. 2014; 33: 4978-4984.
9. Liu X, Qu S, Liu R, et al., TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab. 2014; 99: E1130-E1136.
10. Vinagre J, Almeida A, Populo H, et al., Frequency of TERT promoter mutations in human cancers. Nat Commun. 2013; 4: 2185.
11. Muzza M, Colombo C, Rossi S, et al., Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization. Mol Cell Endocrinol. 2015; 399: 288-295.
12. Landa I, Ganly I, Chan TA, et al., Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab. 2013; 98: E1562-E1566.
13. Gandolfi G, Ragazzi M, Frasoldati A, Piana S, Ciarrocchi A, Sancisi V,. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma. Eur J Endocrinol. 2015; 172: 403-413.
14. Melo M, da Rocha AG, Vinagre J, et al., TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2014; 99: E754-E765.
15. Wang N, Liu T, Sofiadis A, et al., TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. Cancer. 2014; 120: 2965-2979.
16. Hong AR, Lim JA, Kim TH, et al., The frequency and clinical implications of the BRAF(V600E) mutation in papillary thyroid cancer patients in Korea over the past two decades. Endocrinol Metab (Seoul). 2014; 29: 505-513.
17. Song YS, Lim JA, Park YJ,. Mutation profile of well-differentiated thyroid cancer in Asians. Endocrinol Metab (Seoul). 2015; 30: 252-262.
18. Cho BY, Choi HS, Park YJ, et al., Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past four decades. Thyroid. 2013; 23: 797-804.
19. Choi H, Lim JA, Ahn HY, et al., Secular trends in the prognostic factors for papillary thyroid cancer. Eur J Endocrinol. 2014; 171: 667-675.
20. Moura MM, Cavaco BM, Pinto AE, Leite V,. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab. 2011; 96: E863-E868.
21. Cady B, Rossi R,. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988; 104: 947-953.
22. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS,. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993; 114: 1050-1057.
23. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al., Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19: 1167-1214.
24. Edge SB, Compton CC,. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17: 1471-1474.
25. Tuttle RM, Tala H, Shah J, et al., Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010; 20: 1341-1349.
26. de Biase D, Gandolfi G, Ragazzi M, et al., TERT promoter mutations in papillary thyroid microcarcinomas. Thyroid. 2015; 25: 1013-1019.